1. Initial prioritization considerations for new gene/drug pair (may change over time as evidence and experience accumulates)
New Gene/drug pair
Gene already subject to CPIC guideline
Priority 1
Gene not yet subject to CPIC guideline
Actionable in Dutch or other professional society guidelines
Priority 2
Nominated by CPIC member or outside advocate like FDA labeling
Priority 3
PharmGKB Annotation level 1A, 1B, 2A or 2B
Priority 4
Mentioned in professional society guidelines but not actionable
Priority 5
Evaluate alternatives, evidence
Evaluate alternatives, evidence, degree of testing
PharmGKB annotation only: no prescribing action recommended; alternatives unclear or evidence is weak; testing is rare or nonexistent
CPIC guideline: prescribing action recommended; alternative therapies or dosing are highly likely to be effective and safe
CPIC evaluation: no prescribing action recommended; alternatives are unclear, but testing is common